These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 31813613)

  • 21. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
    Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
    Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pomalidomide hybrids act as proteolysis targeting chimeras: Synthesis, anticancer activity and B-Raf degradation.
    Chen H; Chen F; Pei S; Gou S
    Bioorg Chem; 2019 Jun; 87():191-199. PubMed ID: 30901674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and biological evaluation of novel 4,4-difluoro-1-methyl-N, 6-diphenyl-5, 6-dihydro-4H-pyrimido [4, 5-b] [1, 2, 4] triazolo [4, 3-d] [1, 4] diazepin-8-amine derivatives as potential BRD4 inhibitors.
    Li J; Zhang W; Qiu Q; Zhou D; Feng Z; Tong Z; Wei J; Huang W; Li J; Qian H; Shi W
    Chem Biol Drug Des; 2021 May; 97(5):1117-1128. PubMed ID: 33638254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family.
    Fang L; Hu Z; Yang Y; Chen P; Zhou J; Zhang H
    Bioorg Med Chem; 2021 Jun; 39():116133. PubMed ID: 33862375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
    Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
    Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of PROTAC BCL-X
    Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands.
    Wang Z; He N; Guo Z; Niu C; Song T; Guo Y; Cao K; Wang A; Zhu J; Zhang X; Zhang Z
    J Med Chem; 2019 Sep; 62(17):8152-8163. PubMed ID: 31389699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.
    Otto C; Schmidt S; Kastner C; Denk S; Kettler J; Müller N; Germer CT; Wolf E; Gallant P; Wiegering A
    Neoplasia; 2019 Nov; 21(11):1110-1120. PubMed ID: 31734632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and biological evaluation of novel 6-phenyl-1,3a,4,10b-tetrahydro-2H-benzo[c]thiazolo[4,5-e]azepin-2-one derivatives as potential BRD4 inhibitors.
    Li Q; Li J; Cai Y; Zou Y; Chen B; Zou F; Mo J; Han T; Guo W; Huang W; Qiu Q; Qian H
    Bioorg Med Chem; 2020 Aug; 28(15):115601. PubMed ID: 32631570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 3-Hydroxyisoindolin-1-one derivates: Synthesis by palladium-catalyzed CH activation as BRD4 inhibitors against human acute myeloid leukemia (AML) cells.
    Chen P; Yang Y; Yang L; Tian J; Zhang F; Zhou J; Zhang H
    Bioorg Chem; 2019 May; 86():119-125. PubMed ID: 30690335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of the first small molecule histone deacetylase 6 (HDAC6) degraders.
    Yang K; Song Y; Xie H; Wu H; Wu YT; Leisten ED; Tang W
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2493-2497. PubMed ID: 29871848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
    Mu X; Bai L; Xu Y; Wang J; Lu H
    Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, and evaluation of novel pyridone derivatives as potent BRD4 inhibitors for the potential treatment of prostate cancer.
    Jiang W; Wang X; Shu C; Hou Q; Yang K; Wu X
    Bioorg Chem; 2022 Feb; 119():105575. PubMed ID: 34995979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
    Zhou B; Hu J; Xu F; Chen Z; Bai L; Fernandez-Salas E; Lin M; Liu L; Yang CY; Zhao Y; McEachern D; Przybranowski S; Wen B; Sun D; Wang S
    J Med Chem; 2018 Jan; 61(2):462-481. PubMed ID: 28339196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, Synthesis, and in vitro Biological Evaluation of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors.
    Li X; Zhang J; Zhao L; Yang Y; Zhang H; Zhou J
    ChemMedChem; 2018 Jul; 13(13):1363-1368. PubMed ID: 29808961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, and biological evaluation of BRD4 degraders.
    Ding M; Shao Y; Sun D; Meng S; Zang Y; Zhou Y; Li J; Lu W; Zhu S
    Bioorg Med Chem; 2023 Jan; 78():117134. PubMed ID: 36563515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8.
    Sun Z; Deng B; Yang Z; Mai R; Huang J; Ma Z; Chen T; Chen J
    Eur J Med Chem; 2022 Sep; 239():114544. PubMed ID: 35759908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
    Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W
    Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation.
    Liu Z; Chen H; Wang P; Li Y; Wold EA; Leonard PG; Joseph S; Brasier AR; Tian B; Zhou J
    J Med Chem; 2020 May; 63(10):5242-5256. PubMed ID: 32255647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.